• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

所选候选药物的结晶盐形式表现出光、热和湿度诱导的多晶型转变。

The crystalline salt form of a selected candidate drug showed photo-, thermal- and humidity induced form transitions.

机构信息

Advanced Drug Delivery, Pharmaceutical Science, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.

Pharmaceutical Technology & Development, AstraZeneca, Gothenburg, Sweden.

出版信息

Eur J Pharm Sci. 2019 Feb 1;128:128-136. doi: 10.1016/j.ejps.2018.11.028. Epub 2018 Nov 29.

DOI:10.1016/j.ejps.2018.11.028
PMID:30502453
Abstract

AZ3411 was selected as a lead compound for the treatment of Inflammatory Bowel Disease (IBD). The present research aimed to perform an early pharmaceutical assessment of this NK antagonist candidate focusing on the challenging solid-state part of the evaluation. X-ray powder diffraction (XRPD), hot stage XRPD and microscopy, differential scanning calorimetry, thermogravimetrical analysis measurements, nuclear magnetic resonance spectroscopy and liquid chromatographic analysis were used to characterize AZ3411. The amorphous, free base form of AZ3411 was transformed to a poorly crystalline material by salt formation using maleic acid. Suspensions of the poorly crystalline form (type A), prepared in various solvents, exhibited phase transformation on storage. Some precipitate was identified as a new, more crystalline form (type B) of the maleate salt of AZ3411. Also, a third crystalline form was observed at high temperatures (type C). AZ3411 maleate type A, maleate type B and amorphous, free base form was stored in 40 °C/75% relative humidity (RH), 60 °C and 80 °C for three months. Form B was found to be the most chemically stable at all conditions. After three months at 40 °C/75%RH, both type A and type B had transformed to the anhydrous type C. Moreover, type B was transformed to form C at 60 °C and 80 °C, while type A remained unchanged. These results, together with the loss of water with temperature, suggest that type B is a hydrate. The relative stability between the hydrate type B and anhydrous type C depend on humidity and temperature. Moreover, the photosensitivity of maleate type A, maleate type B and amorphous free base has been investigated under three different illumination conditions. In similarity to the previous study, Form B was the most chemically stable form. However, after completion the study, at the highest energy conditions (765 W/m, 250-800 nm), the crystalline type B had transformed to type C, while type A had lost in crystallinity. A similar photostability study was performed on solutions of pH 1 and pH 7. The degradation pattern was similar for the two pHs but appeared different from the unstressed solution stability study performed on different pHs between pH 1 and 7. Neither was there any obvious correlation between the degradation patterns obtained after the stressed thermal- and photostability studies performed on the drug substance in solid-state. The salt of AZ3411 fulfils basic requirements for further development of an oral immediate release (IR) dosage form, although the compound displays signs of light sensitivity and there may be a risk of solid-state transitions during formulation development and long-term storage.

摘要

AZ3411 被选为治疗炎症性肠病(IBD)的先导化合物。本研究旨在对这种 NK 拮抗剂候选药物进行早期药物评估,重点是评估具有挑战性的固态部分。X 射线粉末衍射(XRPD)、热台 XRPD 和显微镜、差示扫描量热法、热重分析测量、核磁共振波谱和液相色谱分析用于表征 AZ3411。AZ3411 的无定形游离碱形式通过使用马来酸形成盐转化为低结晶材料。在各种溶剂中制备的低结晶形式(A型)的混悬液在储存时发生相转变。一些沉淀被鉴定为 AZ3411 的马来酸盐的新的更结晶形式(B 型)。此外,在高温下观察到第三种结晶形式(C 型)。AZ3411 马来酸盐 A、马来酸盐 B 和无定形游离碱形式在 40°C/75%相对湿度(RH)、60°C 和 80°C 下储存三个月。在所有条件下,B 型被发现最稳定。在 40°C/75%RH 下储存三个月后,A 型和 B 型均转化为无水 C 型。此外,B 型在 60°C 和 80°C 下转化为 C 型,而 A 型保持不变。这些结果以及随温度丧失水分表明 B 型是水合物。水合 B 型和无水 C 型之间的相对稳定性取决于湿度和温度。此外,已经在三种不同的光照条件下研究了马来酸盐 A、马来酸盐 B 和无定形游离碱的光敏感性。与之前的研究相似,B 型是最稳定的形式。然而,在完成研究后,在最高能量条件下(765 W/m,250-800nm),结晶 B 型转化为 C 型,而 A 型失去结晶度。在 pH 1 和 pH 7 下进行了类似的光稳定性研究。两种 pH 值的降解模式相似,但与不同 pH 值之间进行的非应激溶液稳定性研究不同。在固态下进行的药物热和光稳定性应激研究后获得的降解模式之间也没有明显的相关性。尽管该化合物显示出光敏感性迹象,并且在制剂开发和长期储存过程中可能存在固态转变的风险,但 AZ3411 的盐符合进一步开发口服即时释放(IR)剂型的基本要求。

相似文献

1
The crystalline salt form of a selected candidate drug showed photo-, thermal- and humidity induced form transitions.所选候选药物的结晶盐形式表现出光、热和湿度诱导的多晶型转变。
Eur J Pharm Sci. 2019 Feb 1;128:128-136. doi: 10.1016/j.ejps.2018.11.028. Epub 2018 Nov 29.
2
Salt formation improved the properties of a candidate drug during early formulation development.成盐改善了候选药物在早期制剂开发过程中的性质。
Eur J Pharm Sci. 2018 Jul 30;120:162-171. doi: 10.1016/j.ejps.2018.04.048. Epub 2018 May 3.
3
Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.制备无定形呋塞米钠盐可提高溶解度和溶出速率,并导致大鼠口服给药后的 Tmax 更快。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):942-51. doi: 10.1016/j.ejpb.2013.09.002. Epub 2013 Sep 27.
4
Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.在高湿度条件下联合储存时,吲哚美辛和精氨酸出现不理想的共无定形现象。
Int J Pharm. 2018 Jun 10;544(1):172-180. doi: 10.1016/j.ijpharm.2018.04.026. Epub 2018 Apr 15.
5
Preformulation investigation and challenges; salt formation, salt disproportionation and hepatic recirculation.制剂前研究及挑战;盐的形成、盐歧化作用和肝肠循环。
Eur J Pharm Sci. 2017 Jun 15;104:262-272. doi: 10.1016/j.ejps.2017.03.041. Epub 2017 Mar 31.
6
Relative humidity-temperature transition boundaries for anhydrous β-caffeine and caffeine hydrate crystalline forms.无水 β-咖啡因和水合咖啡因晶型的相对湿度-温度转变边界。
J Food Sci. 2020 Jun;85(6):1815-1826. doi: 10.1111/1750-3841.15114. Epub 2020 May 25.
7
Stability of polymorphic forms of ranitidine hydrochloride.盐酸雷尼替丁多晶型物的稳定性。
Pharmazie. 2000 Jul;55(7):508-12.
8
Mapping the solid-state properties of crystalline lysozyme during pharmaceutical unit-operations.绘制药物单元操作过程中结晶溶菌酶的固态性质。
J Pharm Biomed Anal. 2015 Oct 10;114:176-83. doi: 10.1016/j.jpba.2015.05.011. Epub 2015 May 22.
9
Preformulation evaluation of AZD1305, an oxabispidine intended for oral and intravenous treatment.AZD1305 的制剂前评价,一种用于口服和静脉治疗的氧杂双环戊烷。
Drug Dev Ind Pharm. 2012 Jan;38(1):19-31. doi: 10.3109/03639045.2011.589452. Epub 2011 Jun 27.
10
Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.无定形喷雾干燥分散体的相分离倾向表征
Mol Pharm. 2017 Feb 6;14(2):377-385. doi: 10.1021/acs.molpharmaceut.6b00722. Epub 2017 Jan 20.